MedRise Medical News

Neuralink’s Week of Firsts: From Mind-Controlled Pizzas to a $9B Valuation

By MedRise News | August 13 2025 | McAllen, Texas

In just seven days, Elon Musk’s Neuralink shattered the boundaries between science fiction and medical reality.

  • U.K. first: Won national approval for GB-PRIME, a groundbreaking feasibility study at University College London Hospitals, enrolling patients with spinal cord injury or ALS.

  • Internet-breaking moment: Showcased patient Audrey Crews—paralyzed since 2005—drawing hearts and pizzas with her mind during a livestream that racked up 11 million views in 48 hours.

  • Investor frenzy: Closed a $650 million Series E, pushing total funding to ~$1.3 billion and valuing the company at $9 billion—with no commercial product yet.

How Neuralink’s Tech Stack Work

Layer - Key Spec - Why It Matters

N1 Implant - 1,024-channel chip - Captures richer motor & sensory data

Flexible threads - 4-6 um wide about 1/14 the width of a human hair - Minimizes brain scarring

R1 Robot - Inserts 64 threads in ~15 minutes with micron precision - Fast, safe, and scalable surgery

Each thread records neuronal spikes. Neuralink’s on-board algorithms decode the user’s intent and send commands via Bluetooth to phones, tablets—even robotic arms.

From “Look” to “Do”

  • Five U.S. trial participants now type, game, and browse the web with cursor control reaching 120 characters per minute.

  • A veteran turns smart-home lights on and off hands-free.

  • Another participant edits CAD models without touching a mouse.

In the GB-PRIME trial, researchers aim to push further—linking the implant to robotic limbs to restore full-body autonomy.

Market Shockwaves

  • Assistive-tech reset – Neuralink’s speed leapfrogs eye-tracking and sip-and-puff systems.

  • Robotics flywheel – Low-latency intention data supercharges prosthetic development.

  • Data goldmine – Continuous neural data could lead to treatments for stroke, ALS, and locked-in syndrome.

Speed Bumps Ahead

  • Safety & longevity: FDA still monitoring for wire migration and battery stability.

  • Ethics & access: Who owns neural data? Will BCIs widen or close disability gaps?

  • Scaling challenge: Each surgery needs an R1 robot and trained specialists; Neuralink wants 100+ implants by 2026.

The Bottom Line

With mind-bending demos, fresh capital, and simultaneous U.S.–U.K. trials, Neuralink has kicked off a global platform race in brain–computer tech. The only question left—for investors, ethicists, and future cyborgs alike—is:

When can I get one?

The message: Brain–computer interfaces (BCIs) are no longer distant dreams. They’re here, rolling out in real clinics.

Disclosure: Author holds no position in Neuralink or its affiliates.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.